Stock Insight
First Solar Could Be a Major Winner From New U.S. Solar Tariffs
First Solar could benefit from new U.S. solar tariffs, but investors still need to watch pricing, policy support, backlog trends and legal risks.
Stock Insight
Analysis of company-specific developments including acquisitions, buybacks, management changes, insider activity, regulation, corporate actions, and business outlook.
Stock Insight
What Another 25–50 Basis Points of Fed Tightening Could Mean for AI Stocks
Another 25–50 basis points of Fed tightening may not end the AI boom, but it could expose weak financing, slower cloud demand and cracks across the data-center supply chain.
Stock Insight
AI Stocks Face a Fed Test: Which Names Are Most Exposed to Higher Rates?
The Fed’s next rate move could test the AI investment boom. We compare Microsoft, Alphabet, Meta, Oracle, CoreWeave, Nvidia, AMD, Arista, Super Micro, Dell and other AI-linked stocks to see which balance sheets are strongest—and which are most vulnerable if higher rates slow data-center spending.
Stock Insight
Sana Biotechnology Could Be a Multibagger—or a Major Loss. Here’s the Risk-Reward Setup
Sana Biotechnology offers high-risk, high-reward biotech exposure, with SC451 and SG293 driving the upside while cash burn and dilution remain major risks.
Stock Insight
Oil Is Back at $100. Which Energy Stocks Are Worth Watching—and Which Are Too Expensive?
Brent is back near $100 a barrel, boosting U.S. energy stocks. We compare EOG, Chevron and Exxon to see which names offer the best risk-reward—and why this may not be the best time to chase oil stocks.
Stock Insight
Circle Is Paying $400 Million for Tazapay. Why CRCL Stock Fell—and What the Deal Could Mean
Circle’s $400 million all-stock acquisition of Tazapay could accelerate its push into global payments, but dilution, regulatory risk and a still-premium CRCL valuation remain key concerns.
Stock Insight
WaFd’s EverBank Merger Could Boost 2027 EPS by 29%. Here’s What WAFD Investors Need to Know
WaFd’s merger with EverBank will heavily dilute existing shareholders, but management expects the larger bank to deliver 29% EPS accretion in 2027 and substantial cost synergies.
Stock Insight
Boston Scientific Could Cut Its 2026 Outlook for a Third Time. Is BSX Stock Finally Cheap?
Boston Scientific may cut its 2026 outlook for a third time after a cyberattack disrupted operations, but BSX’s steep selloff and lower valuation could be creating an opportunity.